AEON Biopharma (NASDAQ:AEON) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of AEON Biopharma (NASDAQ:AEON) in a research report released on Wednesday morning, Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright also issued estimates for AEON Biopharma’s Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.24) EPS.

AEON Biopharma Trading Down 1.5 %

Shares of AEON stock opened at $6.79 on Wednesday. The firm has a 50-day moving average of $10.69 and a 200-day moving average of $7.78. AEON Biopharma has a one year low of $3.37 and a one year high of $17.17.

AEON Biopharma (NASDAQ:AEON) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.71) EPS for the quarter. On average, sell-side analysts forecast that AEON Biopharma will post -1.54 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AEON. Northern Trust Corp raised its stake in shares of AEON Biopharma by 53.4% during the 4th quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock worth $359,000 after purchasing an additional 17,341 shares during the period. Formidable Asset Management LLC bought a new position in AEON Biopharma during the third quarter valued at about $360,000. Vanguard Group Inc. purchased a new stake in AEON Biopharma during the third quarter worth about $1,085,000. Finally, Atalaya Capital Management LP bought a new stake in AEON Biopharma in the third quarter worth about $19,827,000. Hedge funds and other institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.